Home › Funds › Sofinnova Investments, Inc. › MIRM
Sofinnova Investments, Inc. position in MIRM
MIRUM PHARMACEUTICALS INC · Health Care
Sofinnova Investments, Inc. reported holding 19,450 shares of MIRM (MIRUM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$1.7M, representing 0.08% of its reported portfolio and ranking #48 among its reported holdings. Sofinnova Investments, Inc. has disclosed MIRM holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s MIRM position evolved
Sofinnova Investments, Inc. first disclosed a stake in MIRM in Q3 2023 at 9,089 shares (US$287K). The position peaked in Q4 2023 at 352,397 shares, worth US$10.4M. Across 7 filings, Sofinnova Investments, Inc. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 19,450 shares valued at US$1.7M — a reduction of -8,141 shares quarter over quarter.. Notable position changes include a 3777% increase in Q4 2023 (shares fell 15% over the following quarter), a 99% trim in Q1 2024 (shares rose 36% over the following quarter), a 30% trim in Q3 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.09K | $287.21K | New |
| Q4 2023 | 352.40K | $10.40M | Add |
| Q1 2024 | 3.01K | $75.66K | Reduce |
| Q4 2025 | 23.10K | $1.82M | New |
| Q1 2026 | 27.59K | $2.55M | Add |
| Q2 2026 | 27.59K | $3.23M | Hold |
| Q3 2026 | 19.45K | $1.66M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MIRM and 13F data
MIRM (MIRUM PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in MIRM — the largest reported positions include Frazier Life Sciences Management, L.P. (US$899.1M), TANG CAPITAL MANAGEMENT LLC (US$144.7M), Novo Holdings A/S (US$131.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MIRM
- Frazier Life Sciences Management, L.P. 7.68M sh · $899.06M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.24M sh · $144.70M · Q2 2026
- Novo Holdings A/S 1.12M sh · $131.70M · Q2 2026
- BVF INC/IL 1.06M sh · $123.63M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.25M sh · $106.72M · Q3 2026
- TCG Crossover Management, LLC 1.12M sh · $95.65M · Q3 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 24.65M sh · $91.66M · Q2 2026
- Rock Springs Capital Management LP 779.79K sh · $66.66M · Q3 2026
- BAKER BROS. ADVISORS LP 445.98K sh · $52.21M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 415.64K sh · $48.66M · Q2 2026
- Palo Alto Investors LP 348.81K sh · $40.83M · Q2 2026
- EMERALD ADVISERS, LLC 469.77K sh · $40.16M · Q3 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held MIRM?
Sofinnova Investments, Inc. has disclosed MIRM holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Sofinnova Investments, Inc.'s current position in MIRM?
As of Q3 2026, Sofinnova Investments, Inc. holds 19.45K shares of MIRM (MIRUM PHARMACEUTICALS INC), valued at $1.66M, representing 0.08% of its reported portfolio and ranking #48.
Has Sofinnova Investments, Inc. been buying or selling MIRM?
In the latest 13F filing (Q3 2026), Sofinnova Investments, Inc. reduced its position in MIRM. The position peaked in Q4 2023 at 352.40K shares.
Which other funds hold MIRM?
Other major institutional holders of MIRM include Frazier Life Sciences Management, L.P., TANG CAPITAL MANAGEMENT LLC, Novo Holdings A/S, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.